TOKYO, May 15 (Pulse News Wire) – GNI Group Ltd. (2160.T) reported a 20.6% increase in revenue to -¥3.400 billion for the quarter ending March 2026, driven by strong performance across its pharmaceutical and medtech segments.
Operating profit declined to ¥810 million due to expenses related to marketing activities for F351 and stock option accounting adjustments. In the pharmaceutical division, revenue rose to -¥3.400 billion compared to -¥3.400 billion last year, while operating profit was ¥810 million from ¥4.003 billion. Medtech saw record-high sales in the first quarter, reaching ¥1.500 billion, up from ¥1.37 billion, bolstered by contributions from recently acquired ZOO LABO and growth in the US biomaterials business.
Other strategic investments included significant spending on research and development for F351, with Gyre Pharmaceuticals advancing Phase 3 clinical trials. Additionally, the company completed the acquisition of Cullgen, enhancing its biotech capabilities and capitalizing on synergies within the group. Looking ahead, GNI Group expects continued investment in key areas such as F351's IND application and ongoing clinical studies, aiming to strengthen its position in the global healthcare market.
🟡 Confidence: Standard AI-translated content.